Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of crovalimab in atypical hemolytic uremic syndrome
2020-002475-35Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of crovalimab in atypical hemolytic uremic syndrome (aHUS) (3 cohorts), sponsored by Roche. Primary endpoint: Complete thrombotic microangiopathy response. Started Mar 2021; status: active.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2020-002475-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002475-35.